Weight Loss
What Are GLP-1 Medications? How They Work, in Plain English
Updated October 31, 2026 · 7 min read
GLP-1 medications are prescription medicines that act like GLP-1, a hormone your gut releases when you eat. They curb your appetite, slow how fast your stomach empties and help your body release insulin when blood sugar rises. At Padgett in Ocala, the GLP-1 options are personalized compounded semaglutide, from $149 a month, and personalized compounded tirzepatide, from $229 a month.
Padgett Medical Center offers personalized compounded semaglutide and personalized compounded tirzepatide for medically supervised weight loss, in person in Ocala or by telehealth anywhere in Florida.
What is GLP-1?
GLP-1, short for glucagon-like peptide-1, is a hormone made by cells in the lining of your intestine and released when you eat. A review of its physiology lists its main jobs: prompting your pancreas to release insulin and holding back glucagon, which helps limit the rise in blood sugar after a meal. It also slows the movement of food through your gut and appears to help regulate appetite.
Your own GLP-1 doesn't last long. The same review says an enzyme called DPP-4 breaks it down extremely quickly, even before the hormone leaves the gut.
How do GLP-1 medications work?
They switch on the GLP-1 receptor, the docking site on your cells that natural GLP-1 uses, which is why they are also called GLP-1 receptor agonists. NIDDK, part of the National Institutes of Health, says the weight-management ones mimic GLP-1 to act on brain areas that regulate appetite and food intake. The FDA-approved semaglutide and tirzepatide labels say each drug lowers calorie intake, likely by affecting appetite.
They slow your stomach, too. Both labels say the drugs delay gastric emptying, meaning food leaves your stomach more slowly, and the FDA-approved tirzepatide label adds that the delay is largest after the first dose and fades over time. Slower emptying is also why the labels warn that these drugs can change how some pills are absorbed, and why any team planning your surgery or sedation needs to know you take one.
They also help control blood sugar. The labels say each drug boosts insulin release when blood sugar is high and lowers glucagon. For weight loss, NIDDK says these medicines don't replace healthy eating and activity, and that they work better combined with a lifestyle program.
Why do some GLP-1 medications last a whole week?
Because they are built to stay in your body. FDA-approved semaglutide and FDA-approved tirzepatide both bind to albumin, a protein in your blood, which their labels say keeps the drug in your body longer. Their half-lives, the time it takes for the amount in your blood to fall by half, are about 1 week and 5 to 6 days, according to the labels.
What are the main GLP-1 medications?
Three of the medicines NIDDK lists as FDA-approved for long-term weight management act on GLP-1: liraglutide, a daily injection, and semaglutide and tirzepatide, both weekly injections. Since that page was last reviewed in June 2024, FDA has approved orforglipron, a once-daily GLP-1 pill for weight management, and the current FDA-approved semaglutide label adds a once-daily tablet.
NIDDK also notes that FDA-approved liraglutide, semaglutide and tirzepatide each have a version for type 2 diabetes under a different name. Other GLP-1 medicines, such as dulaglutide and exenatide, are used for type 2 diabetes but are not on NIDDK's weight-management list.
FDA-approved tirzepatide stands apart: it also switches on the receptor for GIP, short for glucose-dependent insulinotropic polypeptide, another natural hormone. Its label says lab and animal studies suggest GIP may add to the control of food intake.
How do personalized compounded semaglutide and personalized compounded tirzepatide fit in?
They are Padgett's two GLP-1 options, both weekly injections under the skin. Personalized compounded semaglutide works on one receptor, GLP-1; personalized compounded tirzepatide works on two, GIP and GLP-1. The labels and studies above describe these ingredients in FDA-approved products; they are not results with Padgett's medications.
"Personalized" describes how your dose is set: your provider chooses it, usually starting low, and adjusts it with you over time. You get clear instructions for your exact medication, report side effects as they come up and never change your dose yourself. To weigh the two, compare personalized compounded semaglutide and personalized compounded tirzepatide or read what "personalized compounded" means.
What side effects do GLP-1 medications cause?
Mostly digestive ones. The labels for FDA-approved semaglutide and tirzepatide both list nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, burping, reflux, tiredness and hair loss among the most common. In their weight-loss trials, 73% of people on FDA-approved semaglutide injection and 56% on FDA-approved tirzepatide reported a digestive side effect, versus 47% and 30% on placebo, an inactive look-alike.
The FDA-approved semaglutide label says digestive side effects were reported most often while the dose was being raised, and the FDA-approved tirzepatide label says most nausea, vomiting and diarrhea happened then and decreased over time. NIDDK says most side effects of weight-management medicines are mild and often improve with continued use.
A few risks are serious. Both labels carry a boxed warning: the drugs caused thyroid C-cell tumors in rodents, and it is unknown whether they do in people. Other warnings include pancreatitis, gallbladder disease, kidney injury from dehydration, severe stomach problems, serious allergic reactions, worsening diabetic eye disease in people with type 2 diabetes, and food getting into the lungs during anesthesia or deep sedation. Both drugs can also cause low blood sugar, especially with insulin or a sulfonylurea, and the FDA-approved semaglutide label adds a faster resting heart rate.
The FDA-approved semaglutide Medication Guide says to call your provider right away about severe stomach pain that won't go away or nausea, vomiting or diarrhea that won't stop, and to get medical help right away for swelling of your face, lips, tongue or throat, or trouble breathing or swallowing. Managing GLP-1 side effects covers the other warning signs and what helps with the common side effects.
Who are GLP-1 medications for?
NIDDK says a health care professional may prescribe a weight-management medicine for an adult with a body mass index (BMI) of 30 or more, or 27 or more with a weight-related problem such as high blood pressure or type 2 diabetes. The FDA-approved semaglutide and tirzepatide labels cover adults with obesity, or overweight plus at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. Check your number with the BMI calculator.
They aren't for everyone with a high BMI. NIDDK notes that some people can lose weight with a lifestyle program alone, and says never to take one only to improve the way you look.
Some people shouldn't take them. The labels rule them out if you or a family member has had medullary thyroid carcinoma, a type of thyroid cancer, if you have an endocrine condition called multiple endocrine neoplasia syndrome type 2 (MEN 2), or after a serious allergic reaction to the drug. Both labels also say they aren't recommended for people with severe gastroparesis, a condition in which the stomach empties very slowly.
NIDDK advises against weight-management medicines during pregnancy, when planning one, or while breastfeeding. If you are planning a pregnancy, tell your provider early: FDA-approved semaglutide stays in the blood for about 5 to 7 weeks after the last dose, and its label says treatment should end at least 2 months before a planned pregnancy.
Before you start, tell your provider if you have or have had pancreas or kidney problems or diabetic eye disease, and about every medicine, vitamin and supplement you take, especially insulin or a sulfonylurea. The FDA-approved tirzepatide label also says it may make birth control pills less effective. Is personalized compounded tirzepatide right for you? goes further.
How do you get a GLP-1 medication at Padgett in Ocala?
Your visit is with Sarah Weir, APRN, an advanced practice registered nurse, at 200 SW 8th St., Suite A, just south of downtown Ocala, or by telehealth from anywhere in Florida while you are physically in the state. Your provider decides whether a GLP-1 medication is right for you, and no prescription is promised in advance.
If one is prescribed, your care is medically supervised and your medication is shipped to your door in Florida. At the starting dose, personalized compounded semaglutide is $149 a month and personalized compounded tirzepatide is $229 a month; each service page lists the other doses.
The monthly price is your medication. Your provider visit is $100 and is free when you start medication at that visit; the only other charge is a $50 no-show fee. It applies if you miss the visit or don't cancel or reschedule at least 24 hours ahead, and it can go toward your next visit. There are no contracts, and care is self-pay; see personalized compounded semaglutide without insurance.
Booking online costs nothing, and a card on file holds your visit; without a card, the appointment isn't confirmed until staff reach you by phone. Questions first? Ask for the free consultation: a free 15-minute phone call with the medical staff; it is not a visit with the provider and nothing is prescribed on it.
Rather not inject? Phentermine weight loss in Ocala uses an FDA-approved generic appetite suppressant pill, a Schedule IV controlled substance labeled for short-term use, and not a GLP-1; phentermine vs. personalized compounded semaglutide compares the two.
Ready to start? Book a weight-loss visit, on SW 8th Street or by telehealth, or call (352) 369-0104, Monday to Friday, 9:00 AM to 5:00 PM.
Personalized compounded semaglutide and personalized compounded tirzepatide are compounded drugs that have not been approved by the FDA. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved products containing semaglutide and tirzepatide are available. Individual results vary.
This article is educational and is not medical advice. Talk with a licensed provider about your own health, medications and treatment options.
Pending medical review. This article is educational and is not medical advice. Never start, stop, split or change the timing of a prescription based on something you read online. Your provider decides your dose and your schedule.
Frequently asked questions
Is a GLP-1 medication a type of insulin?
No. GLP-1 medicines are not insulin, and NIDDK says they are not substitutes for it. They prompt your body to release its own insulin, so a person who needs insulin can't simply swap it for a GLP-1. If you use insulin, your prescribers decide any change; don't stop it or adjust it yourself.
Is metformin a GLP-1 medication?
No, metformin is a different diabetes medicine, usually taken as a pill. NIDDK says it helps your liver make less glucose and helps your body use insulin better, and may help you lose a small amount of weight. GLP-1 medicines work through the GLP-1 receptor instead. If you take metformin, tell your provider, and don't stop or change it yourself.
Is there a GLP-1 pill?
Yes. FDA-approved orforglipron is a once-daily GLP-1 pill for weight management, FDA-approved semaglutide comes as a once-daily tablet for weight management too, and NIDDK notes an FDA-approved semaglutide pill for type 2 diabetes. Padgett's GLP-1 options are weekly injections. If you'd rather take a pill, ask your provider about phentermine, which works differently and is not a GLP-1.
Can you take two GLP-1 medications at the same time?
It isn't recommended. The labels for FDA-approved semaglutide, tirzepatide and orforglipron each advise against combining the drug with another GLP-1 medicine. If another doctor already prescribes you one, for diabetes for example, tell your Padgett provider before you start, and don't stop or add either medicine on your own.
How long have GLP-1 medications been around?
More than 20 years. A review of the drug class says the first, exenatide, was approved for type 2 diabetes in 2005 and left the body so quickly that it had to be injected twice a day. The labels for FDA-approved semaglutide and tirzepatide list their first U.S. approvals in 2017 and 2022, and FDA-approved orforglipron was first approved in 2026.
Sources
- Prescription Medications to Treat Overweight & Obesity, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Prescribing information and Medication Guide for FDA-approved semaglutide injection and tablets for weight reduction (Novo Nordisk, revised 6/2026), DailyMed, U.S. National Library of Medicine
- Prescribing information for FDA-approved tirzepatide injection for weight reduction and obstructive sleep apnea (Eli Lilly and Company, revised 8/2026), DailyMed, U.S. National Library of Medicine
- Prescribing information for FDA-approved orforglipron tablets for weight reduction (Eli Lilly and Company, revised 7/2026), DailyMed, U.S. National Library of Medicine
- The physiology of glucagon-like peptide 1, Physiological Reviews, 2007, PubMed
- GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art, Molecular Metabolism, 2021, PubMed
